The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Expansion In Market Value Is Forecasted For The Nodular Prurigo Market Between 2026 And 2030?
The nodular prurigo market size has experienced considerable expansion over recent years. Its projected trajectory indicates an ascent from $1.25 billion in 2025 to $1.33 billion by 2026, progressing at a compound annual growth rate (CAGR) of 6.6%. Historically, this growth was primarily fueled by the increasing prevalence of chronic dermatological disorders, the restricted efficacy of traditional topical therapies, enhanced public awareness of pruritic skin diseases, the proliferation of dermatology specialty clinics, and improvements in the diagnostic recognition of nodular prurigo.
The nodular prurigo market is anticipated to experience substantial growth over the next few years, projected to reach $1.7 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.3%. This expansion during the forecast period can be attributed to the escalating development of novel biologics and monoclonal antibodies, an increasing focus on personalized dermatology treatments, growing investments in inflammatory skin disease research, the broadening of advanced immunotherapy pipelines, and a rising demand for long-term itch control solutions. Prominent trends throughout the forecast period include the increasing adoption of targeted immunomodulatory therapies, a rising utilization of biologic treatments for chronic pruritus, an enhanced focus on neuropathic itch management, the expansion of long-term disease management protocols, and a greater emphasis on patient-centric dermatology care.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24624&type=smp
What Primary Drivers Are Shaping The Nodular Prurigo Market?
The nodular prurigo market is anticipated to expand due to the growing need for targeted therapies. These therapies are medical interventions designed to precisely target and disrupt the molecular mechanisms contributing to disease development and progression. The increasing preference for targeted therapies stems from their capacity to offer more accurate treatments, resulting in fewer adverse effects, better patient results, and new options compared to conventional, less specific approaches. Nodular prurigo contributes to the advancement of targeted therapies by highlighting a distinct unmet medical requirement linked to specific immune pathways like IL-4, IL-13, and IL-31. This facilitates the application of biologics that precisely inhibit these inflammatory signals, leading to more effective treatment. For example, as reported by the American Society of Gene & Cell Therapy, a US-based organization dedicated to gene and cell therapy, in January 2024, the fourth quarter of 2023 saw a 10% increase in Phase III gene therapies compared to the prior quarter. This marked the initial growth observed since Q3 2022. Consequently, the growing demand for targeted therapies is a key factor propelling the expansion of the nodular prurigo market.
How Is The Nodular Prurigo Market Categorized Across Its Segment Groups?
The nodular prurigo market covered in this report is segmented –
1) By Type: Chronic Nodular Prurigo, Acute Nodular Prurigo, Subacute Nodular Prurigo
2) By Treatment Type: Topical Treatments, Systemic Treatments, Phototherapy, Immunosuppressants
3) By Patient Demographics: Adults, Children, Elderly
4) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users
Subsegments:
1) By Chronic Nodular Prurigo: Idiopathic Chronic Nodular Prurigo, Secondary To Dermatologic Conditions, Neuropathic Causes, Systemic Disease-Associated, Psychogenic Prurigo
2) By Acute Nodular Prurigo: Insect Bite-Induced, Allergic Reactions, Drug-Induced Prurigo, Infectious Triggers
3) By Subacute Nodular Prurigo: Healing Phase Of Chronic Prurigo, Post-Inflammatory Prurigo, Transient Dermatoses, Reaction To Environmental Irritants
What Trends Are Affecting The Growth Of The Nodular Prurigo Market?
Leading companies within the nodular prurigo market are concentrating on creating advanced solutions, such as anti-IL-31 receptor biologics, to satisfy the increasing need for disease-modifying treatments that alleviate intense chronic itching, enhance nodule resolution, and decrease dependence on long-term topical corticosteroids and broad immunosuppressants. An anti-IL-31 receptor monoclonal antibody is a biologic treatment composed of engineered humanized antibodies designed to attach to the IL-31 receptor A on sensory and immune cells, thereby inhibiting IL-31 signaling, which is linked to chronic pruritus. For example, in August 2024, Galderma S.A., a dermatology pharmaceutical company based in Switzerland, introduced Nemluvio (nemolizumab), a novel anti-IL-31 receptor monoclonal antibody intended for adults suffering from prurigo nodularis. Nemluvio (nemolizumab) is a humanized monoclonal antibody, administered via subcutaneous injection, that binds to IL-31 receptor A to disrupt itch signaling and subsequent inflammatory pathways; it was developed to diminish severe chronic itch and encourage the healing of pruritic nodules, and is provided as an autoinjector for convenient outpatient application. Its distinct characteristics include a targeted mechanism, systemic efficacy suitable for widespread conditions, and a dosing method aimed at improving patient compliance compared to clinic-administered infusions.
Which Firms Are Influencing Competition In The Nodular Prurigo Market?
Major companies operating in the nodular prurigo market are Merck and Co Inc, Sanofi SA, GlaxoSmithKline plc, Amgen Inc, Regeneron Pharmaceuticals Inc, Astellas Pharma Inc, Sun Pharmaceutical Industries Limited, Galderma SA, Incyte Corporation, Kyowa Kirin Co Ltd, LEO Pharma AS, Maruho Co Ltd, Kiniksa Pharmaceuticals Ltd, Keymed Biosciences Co Ltd, Trevi Therapeutics Inc, Menlo Therapeutics Inc, VYNE Therapeutics Inc, Celldex Therapeutics Inc, AbbVie Inc, Pfizer Inc, Novartis AG, Eli Lilly and Company
Get The Full Nodular Prurigo Market Report:
https://www.thebusinessresearchcompany.com/report/nodular-prurigo-global-market-report
Which Region Represents The Largest Share Of The Nodular Prurigo Market?
North America was the largest region in the nodular prurigo market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nodular prurigo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Nodular Prurigo Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/nodular-prurigo-global-market-report
Browse Through More Reports Similar to the Global Nodular Prurigo Market 2026, By The Business Research Company
Neuralgia Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/neuralgia-treatment-global-market-report
Dental Sleep Medicine Market Report
https://www.thebusinessresearchcompany.com/report/dental-sleep-medicine-global-market-report
Urea Cycle Disorders Treatment Market Report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model